XBI is trading 3.17% down now at $151.24, with broad-based negative sentiment across biotechnology weighing on the sector.
- The sector update cites increased risk aversion toward clinical-stage companies, with no single major catalyst identified.
- Major U.S. indexes are higher, so the move does not appear to reflect a broad-market decline.
- No XBI-specific catalyst has been identified.